Hikma Pharmaceuticals Plc Hikma and Civica Rx sign long-term agreement
July 23 2019 - 4:00AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
23 July 2019
London and Salt Lake City, UT, July 23, 2019 - Hikma
Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK)
(OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable), the
multinational generic pharmaceutical company and Civica Rx (Civica,
Inc.) today announce a five-year agreement to manufacture and
supply Civica's growing membership of US health systems with
medications that are often in short supply in US hospitals.
Under the agreement, Hikma will produce 14 essential sterile
injectable medications for Civica as a private label distributor,
using Hikma's Abbreviated New Drug Applications (ANDAs) and
Civica's labeling and National Drug Code (NDC). These medicines are
used daily by hospitals in emergency care, surgery, pain management
and in treating hypertension. The list of products included in the
agreement will be publicly announced in the near future, and
initial shipments are expected to begin before the end of 2019.
Civica was founded in 2018 by leading US hospital systems
concerned about generic drug shortages and philanthropic
organisations passionate about improving healthcare. To date more
than 30 health systems are Civica members, representing more than
900 US hospitals and approximately 30 percent of all licensed US
hospital beds.
Hikma is the third largest US supplier of generic injectable
medicines with a growing portfolio of more than 100 injectable
products. Today, one in every six generic injectable medicines used
in US hospitals is a Hikma product. During the last three years,
Hikma has launched more than 20 medications into US shortage
situations and in 2016 the company received a Drug Shortage
Assistance Award from the US Food and Drug Administration (FDA) for
its role in preventing or alleviating drug shortages.
"Hikma is thrilled to be partnering with Civica to reduce drug
shortages, and we share their commitment to providing hospitals and
doctors with a steady and reliable supply of high-quality
injectable medicines needed for successful patient care," said
Daniel Motto, Hikma's EVP of Commercial & Business Development,
US Injectables. "This agreement recognises both our ability to
deliver a large and consistent supply of quality medicines, and the
significant investments we have made to expand our injectable
manufacturing capacity and capabilities."
"We applaud Hikma's clear commitment to reducing drug
shortages," said Martin VanTrieste, President and CEO of Civica Rx.
"Our partnership will help us make an impact as quickly as
possible. We specifically chose Hikma because of their strong
manufacturing capabilities and believe their excellent quality and
supply record will be key to our success in ensuring vital
medications are consistently available for hospitals and patients
who need them."
"We are privileged to be working with Civica and we appreciate
their five-year commitment to guaranteed demand and fair and
sustainable pricing, which supports more effective production
planning and long-term investments in manufacturing," said Riad
Mishlawi, President, Hikma Injectables. "We believe Hikma's size
and scale, broad portfolio of medicines and robust pipeline across
growing therapeutic areas will enable us to build on this
partnership in the future. We are committed to working with Civica
and all of our customers as a reliable partner, capable of serving
the growing needs of US hospitals and clinics for a wide-range of
essential medicines."
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal +44 (0)20 7399 2760/ +44 7776
EVP, Strategic Planning and Global 477050
Affairs uk-investors@hikma.com
Steven Weiss +1 732 720 2830/ +1 732 788 8279
Senior Director, Communications sweiss@hikma.com
and Public Affairs
Civica Rx
Debbi Ford +1 970 227 3991
Debbi.ford@civicarx.org
About Civica Rx
Civica was established in 2018 to reduce chronic generic drug
shortages in the US and exists in the public interest as a
non-profit, non-stock corporation committed to stabilising the
supply of essential generic medications in a hospital setting.
Civica's membership includes a Governing Board and Founding and
Partnering Members.
Civica will act in the best interest of patients to eliminate
uncertainty in the generic drug supply chain through long-term
contracts with health system members as well as its manufacturing
partners. Civica is committed to transparency and will offer fair
and sustainable prices to its member hospitals. It will also ensure
it has dedicated manufacturing capacity for the medications that
are most desperately needed in hospitals across the country through
redundant manufacturing and strategic stockpiling of medications to
prevent drug shortages in the future.
Civica aims to stabilise the supply of antibiotics, anesthetics,
cardiac medications, pain management medications, and other
essential sterile injectable medicines used in hospitals daily. It
is actively pursuing a three-pronged product supply strategy:
-- Working with multiple generic drug manufacturers that have
the US FDA approved manufacturing facilities and capacity to
produce Civica labeled generic drugs, allowing manufacturers to
re-enter the market or increase existing capacity
-- Developing and acquiring Abbreviated New Drug Applications
(ANDAs) for generic drugs and working with contract manufacturing
organizations to produce Civica medications
-- Acquiring and building Civica manufacturing facilities using Civica's ANDAs
More information about Civica can be found at www.civicarx.org
and https://civicarx.org/media/.
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. We are a global
company with a local presence across the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,400 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADXLBLKDFLBBV
(END) Dow Jones Newswires
July 23, 2019 04:00 ET (08:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024